Essity Cutimed Sorbact advanced wound care products receive innovative technology contract from Vizient

166

Cutimed Sorbact (from Essity) has received a 2021 Innovative Technology contract from Vizient, the largest member-driven, healthcare performance improvement company in the USA. 

The contract was awarded based on the recommendations of health care experts serving on a Vizient member-led council who interacted with the product through the Vizient Innovative Technology programme. The council determined the technology had the potential to enhance clinical care, patient safety, health care worker safety, or improve business operations of health care organisations.

According to Essity, Cutimed Sorbact redefines infection management with a physical mode of action, helping to promote wound healing and, in some cases, helping to reduce the risk of generating resistant strains of bacteria. Hydrophobic bacteria and fungi are attracted to the Sorbact mesh, which is applied directly to the wound, and bound pathogens are removed with each dressing change with an average bacterial load reduction of up to a 73.1% in critically colonised wounds. Sorbact binds and lifts away pathogens, rather than killing them, ensuring no endotoxins are released which could impair recovery.

“Hospitals and providers are looking for innovations that offer unique benefits over other products available on the market today. Our member council determined this technology met the criteria to be awarded the Innovative Technology contract. Congratulations to Essity on receiving this status,” comments Debbie Archer, director of Procurement and Vizient Innovative Technology programme.

Essity also recently launched the #Wound_Warriors campaign in an effort to fight antimicrobial resistance (AMR). AMR occurs when microorganisms change and adapt, after exposure to antimicrobial drugs. As these microorganisms adapt, many medical treatments are rendered ineffective and thus infections can remain in the body and spread more easily to others. In 2015, the World Health Organization (WHO) identified AMR as one of the world’s most pressing drug resistance trends and launched a Global Action Plan on AMR. Through the ‘Woun_Warriors campaign, Essity is furthering this mission and encouraging wound care specialists and nurses to join in the fight against AMR by including Cutimed Sorbact in their practice, a company press release states.

LEAVE A REPLY

Please enter your comment!
Please enter your name here